You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,306,598


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,306,598
Title: Nucleic acid-coupled colorimetric analyte detectors
Abstract:The present invention relates to methods and compositions for the direct detection of analytes and membrane conformational changes through the detection of color changes in biopolymeric materials. In particular, the present invention provide for the direct colorimetric detection of analytes using nucleic acid ligands at surfaces of polydiacetylene liposomes and related molecular layer systems.
Inventor(s): Charych; Deborah H. (Albany, CA), Jonas; Ulrich (Mainz, DE)
Assignee: Regents of the University of California (Oakland, CA)
Application Number:09/337,973
Patent Claims:1. A composition comprising one or more biopolymeric materials comprising a plurality of polymerized self-assembling lipid monomers and one or more nucleic acid ligands, wherein binding of an analyte to said nucleic acid ligand causes a conformational change in said polymerized self-assembling lipid monomers, resulting in a color change in said biopolymeric materials.

2. The composition of claim 1, wherein said one or more nucleic acid ligands are capable of binding to said analyte.

3. The composition of claim 1, wherein said one or more nucleic acid ligands are single-stranded nucleic acid sequence.

4. The composition of claim 1, wherein said one or more nucleic acid ligands are linked to said polymerized self-assembling lipid monomers through one or more covalent bonds.

5. The composition of claim 4, wherein said one or more covalent bonds are selected from the group consisting of amine bonds, thiol bonds, and aldehyde bonds.

6. The composition of claim 2, wherein said analyte is selected from the group consisting of nucleic acid molecules, enzymes, pathogens, drugs, receptor ligands, antigens, ions, proteins, hormones, blood components, antibodies, and lectins.

7. The composition of claim 6, wherein said nucleic acid moleules are selected from the group consisting of ribosomal RNA, transfer RNA, messenger RNA, intron RNA, double-stranded RNA, single-stranded RNA, single-stranded DNA, double-stranded DNA, nucleic acid sequences characteristi of human pathogens, nucleic acid sequences characteristic of non-human pathogens, and nucleic acid sequences characteristic of genetic abnormalities.

8. The composition of claim 6, wherein said enzymes are selected from the group consisting of polymerases, nucleases, ligases, telomerases and transcription factors.

9. The composition of claim 6, wherein said pathogens are selected from the group consisting of viruses, bacteria, parasites, and fungi.

10. The composition of claim 1, further comprising one or more dopant materials.

11. The composition of claim 10, wherein said dopant material is selected from the group consisting of surfactants, polysorbate, octoxynol, sodium dodecyl sulfate, polyethylene glycol, zwitterionic detergents, decylglucoside, deoxycholate, diacetylene derivatives, phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine, phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylmethanol, cardiolipin, ceramide, cholesterol, steroids, cerebroside, lysophosphatidylcholine, D-erythroshingosine, sphingomyelin, dodecyl phosphocholine, and N-biotinyl phosphatidylethanolamine.

12. The composition of claim 11, wherein said diacetylene derivatives are selected from the group consisting of sialic acid-derived diacetylene, lactose-derived diacetylene, and amino acid-derived diacetylene.

13. The composition of claim 1, further comprising one or more non-nucleic acid ligands.

14. The composition of claim 13, wherein said one or more non-nucleic acid ligands are selected from the group consisting of carbohydrates, proteins, drugs, chromophores, antigens, chelating compounds, molecular recognition complexes, ionic groups, polymerizable groups, linker groups, electron donors, electron acceptor groups, hydrophobic groups, hydrophilic groups, receptor binding groups, trisaccharides, tetrasaccharides, ganglioside G.sub.M1, ganglioside G.sub.T1b, sialic acid, and combinations thereof.

15. The composition of claim 1, wherein said one or more biopolymeric materials comprise biopolymeric films.

16. The composition of claim 1, wherein said one or more biopolymeric materials comprise biopolymeric liposomes.

17. The composition of claim 1, wherein said one or more biopolymeric materials are selected from the group consisting of tubules, braided assemblies, lamellar assemblies, helical assemblies, fiber-like assemblies, solvated rods, and solvated coils.

18. The composition of claim 1, wherein said self assembling monomers comprise diacetylene monomers.

19. The composition of claim 18, wherein said diacetylene monomers are selected from the group consisting of 5,7-docosadiynoic acid, 5,7-pentacosadiynoic acid, 10,12-pentacosadiynoic acid, and combinations thereof.

20. The composition of claim 1, wherein said self-assembling monomers contain head groups selected from the group consisting of carboxylic acid, hydroxyl groups, amine groups, amino acid derivatives, and hydrophobic groups.

21. The composition of claim 1, further comprising a support, and wherein said one or more biopolymeric materials are immobilized to said support.

22. The composition of claim 21, wherein said support is selected from the group consisting of polystyrene, polyethylene, teflon, mica, sephadex, sepharose, polyacrynitriles, filters, glass, gold, silicon chips, and silica.

23. A device comprising said one or more of the biopolymeric materials of claim 1, wherein said one or more biopolymeric materials are immobilized to said device.

Details for Patent 6,306,598

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2012-11-13
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2012-11-13
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2012-11-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.